Clinical trial NCT05835921: Enhancing Prospective Thinking in Early Recovery
Official title: Enhancing Prospective Thinking in Early Recovery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stimulant Use
Substance Use Disorders
Lead sponsor: Indiana University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2023-04-28
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups:

Experimental Group Control Group
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing stimulant use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering stimulant use disorder (StUD) persons. The main question\[s\] this trial aims to answer are:

* Will the Virtual Reality (VR) intervention decrease the number of stimulant use days?
* Will the VR intervention produce longer abstinence periods during follow-up visits?
* Will the VR intervention increase stimulant drug abstinence rates?
* Will the VR intervention increase future self-identification?
* Will the VR intervention increase self-reported future time perspective?
* Will the VR intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day?
* Will the VR intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups?

Researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above.


Eligibility criteria: Inclusion Criteria:

* Abstinence between ≥14 days and ≤1 year
* At least 18 years old
* Verbal endorsement of commitment to recovery
* Outpatient
* Psychotropic drugs for SUD-comorbidity
* Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
* English comprehension

Exclusion Criteria:

* Unstable medical disorders
* Less than 18 years old
* Habitual drug use
* Mu-opioid drugs
* Smell/taste disorders
* Unstable psychiatric conditions
* Extravagant/elaborate face tattoos

Primary outcomes:
measure: Reduced Use of Drug Using Days
timeFrame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
measure: Increased Length of Abstinence
timeFrame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
measure: Increased (overall) Abstinence
timeFrame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
measure: Future Self-identification
timeFrame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
measure: Future Time Perspective
timeFrame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
measure: Delayed Reward Preference
timeFrame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Indiana University School of Medicine - Goodman Hall
state: Indiana
Study officials:
affiliation: Indiana University
name: Brandon G Oberlin, PhD
role: PRINCIPAL_INVESTIGATOR
References: